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Genomic structural alteration is common in pediatric cancers, and analysis of data generated by the
Pediatric Cancer Genome Project reveals such tumor-related alterations in manyWnt signaling–associated
genes. Most pediatric cancers are thought to arise within developing tissues that undergo substantial
expansion during early organ formation, growth andmaturation, andWnt signaling plays an important role
in this development. We examined three pediatric tumors—medullobastoma, early T-cell precursor acute
lymphoblastic leukemia, and retinoblastoma—that showmultiple genomic structural variationswithinWnt
signaling pathways. We mathematically modeled this pathway to investigate the effects of cancer-related
structural variations on Wnt signaling. Surprisingly, we found that an outcome measure of canonical Wnt
signaling was consistently similar in matched cancer cells and normal cells, even in the context of different
cancers, different mutations, and different Wnt-related genes. Our results suggest that the cancer cells
maintain a normal level of Wnt signaling by developing multiple mutations.
C
urrent international efforts to identify oncogenic somatic mutations have revealed that not only single
nucleotide variations but also genomic structural variations (SVs) play a key role in human cancers1,2. In
fact, SVs are the main mutations that drive many pediatric cancers3–6. Given the immense complexity of
some structural alterations, the full set of SVs implicated in oncogenesis would best be identified from whole-
genome sequencing data7,8. By mapping partial reads to a reference genome, the newly developed CREST
(ClippingReveals Structure) algorithmswere able to identify reads spanning the junctions of SVswith a validation
rate greater than 80%. Using data from the current St. Jude Children’s ResearchHospital–Washington University
Pediatric Cancer Genome Project (PCGP)3, such approach has identified many SVs in medulloblastoma (MB)6,
early T-cell precursor acute lymphoblastic leukemia (T-ALL)4, and retinoblastoma (RB)9. Examining the SVs in
the three cancers, we observed a very high frequency of somatic SVs in canonicalWnt signaling–associated genes:
41.3% in T-ALL (38/92 patients), 50% in RB (2/4 patients), and 61.8% in MB (47/76 patients). However, within
even a single type of cancer, SVs spanned almost the entire canonicalWnt signaling pathway. Further, most cases
had multiple Wnt gene structural mutations (Fig. 1a). Therefore, a systems biology analysis equipped by a
mathematical model is needed to investigate the consequences of these mutations and their effect on the Wnt
signaling pathway in individual patients10.
Results
Because dysregulation of the canonical Wnt signaling pathway can cause aberrant cell proliferation and chro-
mosome instability, the canonical pathway has been extensively studied11,12. In the absence ofWnt signaling, axin,
APC, and GSK-3b form a complex that phosphorylates b-catenin, targeting it for proteasomal degradation.
CanonicalWnt signaling is activated by the binding ofWnt protein to its co-receptors Frizzled (FzD) and LRP5/6.
The dimerization of these two receptors transduces Wnt signal into the cell, destroying axin/APC/GSK-3b and
stabilizing cytoplasmic b-catenin. As a consequence, b-catenin translocates to the nucleus where, in association
with TCF, it activates Wnt target genes13.
Lee et al14 first used a mathematical model to describe the canonical Wnt signaling pathway. The model has
since been extended to include additional protein-protein interactions15–18. Moreover, the model recently pre-
sented by Kogan et al19 explicitly describes extracellular signal initiation and regulatory interactions of two major
Wnt signaling antagonists, Dickkopf (DKK) and soluble frizzled-related protein (sFRP)20,21. To incorporate as
many elements of the Wnt pathway as possible, we integrated several existing models to form a single, compre-
hensive mathematical model of the canonical Wnt signaling pathway containing 14 ordinary differential equa-
tions (ODEs) and 24 variables (14 independent and 10 dependent) that explicitly represent nearly all major
interactions and components of theWnt pathway. Ourmodel, which has been validated (Supplementary Fig. S2)
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by comparison with others14,19, uses the intracellular b-catenin level
as a measure of Wnt signaling outcome (also termed Wnt signaling
output). Parameter sensitivity was analyzed as described by
Goentoro et al22. We found that the parameters most sensitive to
perturbation were those associated with Dishevelled (Dvl); a 5-fold
increase in those parameters resulted in a slightly greater than 3-fold
increase in Wnt signaling output. Nevertheless, the change in Wnt
signaling outcome was, overall, relatively insensitive to the perturba-
tion of individual Wnt signaling–associated genes (Supplementary
Figure S3). This result is consistent with analysis using the model
described by Lee at al14.
Using our mathematical model, based on a notion that globally
there is indeed an appreciable correlation between mRNA levels and
gene copy number23, we examined how SVs in cancer cells affect the
outcome of Wnt signaling by comparing b-catenin levels (i.e., Wnt
signaling outcomes) in cancer cells carrying SVs to those in normal
cells from the same PCGP patient. An increasing concentration of
Wnt ligands induces a progressively increasing cellular b-catenin
level until b-catenin reaches a plateau14,22, and both sFRP and DKK
inhibit this progressive accumulation of b-catenin. To maximize the
sensitivity of the comparisons, we elected to compareb-catenin levels
in the presence of 0.25 nM Wnt, 1 nM sFRP, and 0.5 nM DKK, as
these concentrations are consistent with the midpoint of b-catenin
accumulation (i.e., half of the saturated b-catenin level) and are most
sensitive to variations in other Wnt signaling parameters. b-catenin
levels in malignant cells were converted toWnt signaling output as a
percentage of b-catenin levels in matched normal cells (assigned a
value of 100%) (Fig. 1A, Supplementary Table S4).
Surprisingly, b-catenin levels in most patients’ cancer cells were
within approximately 10% of levels in germline cells; in all three
cancer types, b-catenin levels in cancer cells showed a Gaussian
distribution, peaking near the peak levels in normal cells. In patients
with MB, the mean peak b-catenin level in malignant cells was
99.59% of that in normal cells, and the Gaussian distribution width
of the cancer-cell b-catenin level was 10.09% that of the germline-cell
b-catenin level (Fig. 1B). b-catenin levels were similarly distributed
in T-ALL patients’ cancer cells; the mean peak b-catenin level in
cancer cells was 98.42% of that in normal cells and the Gaussian
distribution width was 10.38% of that in germline cells (Fig. 1C).
When the three types of cancers were combined, the overall mean
Figure 1 | Comparison ofWnt signaling output in matched cancer cells and normal cells. (A) b-catenin levels in cancer cells vs. normal cells according
to cancer type and genomic SV. SVs (equivalent to copy number variations) inWnt signaling–associated genes inMB, ALL, and RB patients studied in the
PCGP are listed in the upper panel. There are five subgroups (Wnt, SHH, group 3, group 4, and unclassified) within MB. In the lower panel, the
calculated b-catenin level is shown as a percentage of the b-catenin level inmatched normal cells. (B) Distribution of b-catenin levels inMB cells with SVs
in Wnt signaling genes. (C) Distribution of b-catenin levels in T-ALL cells with SVs in Wnt signaling genes. (D) Distribution of b-catenin levels in the
malignant cells of all studied patients (the MB, TALL, and RB tumor groups). Values in panels b, c, and d are the number of cases within a range of 10
percentage points. The green lines are the fitted Gaussian distributions.
www.nature.com/scientificreports
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peak b-catenin level was 98.98% of that in normal cells and the
Gaussian distribution width of b-catenin levels in cancer cells was
12.28% of that in germline cells (Fig. 1D).
Discussion
The results of our computational studies suggest that canonical Wnt
signaling activity is normally distributed in cancer cells and has a
mean value approximating that in normal cells. The very few outlier
values we observed may reflect the limitations of our mathematical
model, which is the most comprehensive model of canonical Wnt
signaling to date but is unlikely to account for all components of the
pathway. For example, Dvl expression was substantially upregulated
in four of the five cases of MB (SJMB020, SJMB036,SJMB038, and
SJMB085) that had unusually high b-catenin values (Fig. 1a). Dvl is
well documented to havemany binding partners24–26, the identities of
which are only partially known27. Therefore, high Wnt signaling
output in these four cases may reflect the absence of Dvl regulators
from our model. In addition, our model lacks integrated feedback
loops28. Such an omission may also have introduced calculation
errors that account for outlier values.
Canonical Wnt signaling is a key mechanism in tissue develop-
ment. Because dysregulation of tissue development is thought to be
linked to oncogenesis in children, it was not surprising that almost
half the tumors we examined showed a large number of mutations.
What was surprising, however, were the similar levels of Wnt signal-
ing (i.e., levels of b-catenin) in cancer cells and in the corresponding
germline cells in most of the studied tumors, despite multiple muta-
tions in theWnt pathway. Our data suggest that during development,
tumor cells generate multiple mutations to maintain normal Wnt
signaling output under environmental pressure. Indeed, like other
signaling pathways28, canonical Wnt signaling pathway has feedback
loops. For example, in the pathway, Axin functions as an inhibition
factor; and it was reported that Axin2 is a direct target of the path-
way29. In the three pediatric cancers we examined, we found that 20
patients had upregulation of Axin2 (Supplementary Table S5).
Interestingly, 12 out of the 20 had very highWnt signaling outcome.
The 12 cases actually represented almost all the patients who had
highWnt signaling outcome in our study (Figure 1A, Supplementary
Tables S4 and S5).Moreover, within the 12, except one outliner, there
is a clear linear correlation between Axin2 SVs and Wnt signaling
outcomes (Supplementary Figure S4) suggesting a likely feedback
mechanism. Therefore, these mutations in the Wnt signaling path-
way are unlikely to act as drivers of the primary cancer in these
patients. This conclusion is consistent with a previous report that
b-catenin staining of ALL samples suggested no upregulation
of canonical Wnt signaling30. In addition, abnormal b-catenin
immunoreactivity was absent from MB samples except in the Wnt
subgroup31. Moreover, in our study only 2 of 12 patients in this Wnt
subgroup had SVs in canonical Wnt signaling–associated genes,
while tumor cells in 8 of the 12 patients expressed b-catenin–stabil-
izing mutants6. Interestingly, many of these cases also revealed mis-
sense mutations in the DEAD-box RNA helicase DDX3X at
chromosome Xp11.3. Because DDX3 is reported to promote Wnt
signaling32, it is likely that these missense mutations balance the
effects of the b-catenin–stabilizing mutants in the tumor cells.
Even when normal Wnt signaling output is maintained in tumor
cells via abnormal Wnt signaling pathways, these Wnt pathways
are clearly much less stable than those in normal cells. For example,
when we artificially activated Wnt signaling in our model, some
cancer cells showed much higher Wnt activity than did normal cells
(Supplementary Figure S5A). Therefore, whenmetastatic tumor cells
reach a new environment, their Wnt signaling output may not be
maintained. In such a case, it is very possible that abnormal Wnt
signaling becomes a cancer driver in the new site. On the other hand,
our finding of similar Wnt signaling outcome in malignant and
germline tissue despite multiple Wnt pathway mutations provides
a novel opportunity for targeted therapy for the three pediatric can-
cers examined. Due to the mutations, the Wnt signaling pathways
in tumor and germline tissue were not identical, despite their similar
b-catenin output. Therefore, an inhibitor that targets a specific
protein-protein interaction within the pathway may disrupt abnor-
mal Wnt signaling in tumor cells while sparing Wnt signaling in
normal cells, thereby disrupting tumor growth while maintaining
normal tissue development. Many small-molecule Wnt signaling
regulators, inhibitors, and activators that target different protein-
protein interactions have been developed and characterized33,34;
and our calculations indicate that they have different effects on
Wnt signaling in cancer cells in different patients (Supplementary
Figure S5B). Therefore, a systems biology analysis using amathemat-
ical model like the one described here should be able to use the
mutations revealed by whole-genome sequencing to identify a
small-molecule regulator or combination of regulators that most
effectively disrupts cancer cell growth while maximally sparing nor-
mal cells10,35. Making use of such therapeutic opportunities may rep-
resent the future of genome-based personalized medicine.
Methods
Mathematicalmodel.Ourmodel explicitly represents each knownmajor component
of the canonical Wnt signaling pathway. As shown in Supplementary Figure S1, this
model focuses on the following events: a) Extracellular activation ofWnt signaling by
binding of Wnt protein to FzD and LRP, and antagonism of Wnt signaling by
competitive binding of FRP and DKK to FzD and LRP, respectively; b) Activation of
Dvl by the Wnt-LRP-FzD ternary complex; c) Deactivation by Dvl of the APC-axin-
GSK destruction complex, which binds to b-catenin and results in b-catenin
phosphorylation and degradation, thereby stabilizing b-catenin levels.
Using the assumption of well-mixing and the law of mass action for all protein
interactions in our model, we rewrote the key extracellular and membrane interac-
tions into 7 ODEs and combined them with the original 7 ODEs of Lee et al14 by
replacing the Wnt concentration with the Wnt-LRP-Fzd complex concentration
(Supplementary Table S1). This model contains 24 variables (14 independent and 10
dependent variables) (Supplementary Table S2). The partition coefficient Ksu-ex
introduced by Kogan et al19, which transforms the values of the signals in the cell
membrane to extracellular concentrations, was retained to compute reactions
between components measured by different units in extracellular solution and
membrane. The rate of each reaction and the original concentration of each protein
were obtained directly from the parameters of Kogan et al19 for modeling of extra-
cellular and membrane reactions and the parameters of Lee et al14 for intracellular
reactions (Supplementary Table S3). The model was solved numerically by the ODE
solver ODE15s in the MATLAB software package. The Wnt signaling pathway
contains 16 Wnt subtypes, 10 Frizzled subtypes, 2 LRP subtypes, 5 sFRP subtypes, 3
DKK subtypes (DKK3 is not involved inWnt signaling), 3 Dvl subtypes, and two axin
subtypes. Each protein subtype was assumed to have the same kinetic parameters and
the same physiological concentration.
Model validation. Our model was compared with the models reported by Lee et al14
and Kogan et al19. The b-catenin levels were calculated as the functions of the Wnt
concentration in the three models, respectively. In general, b-catenin accumulation
profiles generated by the three models were consistent. Because the valid Wnt
concentration range formodeling studies was suggested to be 0 nM to 1.4 nM14, all of
the simulations were performed within this range. The calculated Wnt dose–
dependent activation results showed that the b-catenin level increases rapidly asWnt
concentration rises from 0 nM to 0.5 nM, then reaches its saturation point
(Supplementary Fig. S2A), consistent with the profile generated by the model of Lee
et al14. The profile generated by the model of Kogan et al19 reaches saturation at a
slightly lower Wnt concentration.
Using our model, we studied the inhibitory effects of sFRP and DKK at a fixed
concentration (0.5 nM) of Wnt (Supplementary Figure S2B, C). The calculated IC50
values were 11 nM for sFRP and 1.8 nM for DKK1, closely approximating the results
obtained by using the model of Kogan et al19 and within the ranges of the experi-
mentally determined IC50s of the two inhibitors20,21. We also examined the combin-
atorial inhibitory effects of adding both sFRP and DKK, and the resulting b-catenin
concentrations in cells agreed well with that calculated by using the model of Kogan
et al19 (Supplementary Figure S1D). These results confirmed that our model is fully
compatible with the two existing models within a Wnt concentration range of 0 to
1.4 nM.
Wnt signaling output in cancer cells.Ourmathematical model was used to examine
the effect of SVs of Wnt signaling pathway elements on Wnt signaling outcomes in
the cancer cells of PCGP patients. We used cellular b-catenin concentration as the
measure of Wnt signaling outcome/output and calculated b-catenin levels in cancer
cells as a percentage of levels in matched germline cells. As the concentration of Wnt
ligands increases, the concentration of cellular b-catenin also increases until it reaches
a plateau14,22, and both sFRP and DKK inhibit the accumulation of b-catenin induced
www.nature.com/scientificreports
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by Wnt signaling. To maximize the sensitivity of comparisons, we compared b-
catenin levels in the presence of 0.25 nM Wnt, consistent with the midpoint of b-
catenin accumulation (i.e., in the presence of 0.25 nMWnt, the level of b-catenin is at
half the saturated level); this concentration is most sensitive to variations in other
parameters of the Wnt signaling pathway (Supplementary Figure S2A). Under these
conditions, the b-catenin levels in cancer cells with Wnt signaling gene variations
were calculated and expressed as a percentage of the b-catenin levels in normal cells
(assigned a value of 100%). Various physiological concentrations of sFRP and DKK
have been reported20,21; on the basis of our computational studies of their inhibitory
effects, we chose reference concentrations of 1 nM sFRP and 0.5 nM DKK, the
concentrations at which the inhibitory effects of the two components are most
sensitive to changes in their concentration (Supplementary Figure S2B–D). Other
parameters were obtained frompublished reports. Supplementary Table S4 details the
variations in expression of genes in theWnt signaling pathway in the studied patients.
Using our model, we computed the Wnt signaling output of the cancer cells and
normal cells of individual PCGP patients.Wnt output in cancer cells was expressed as
a percentage of output in the respective matched normal cells; the data are shown in
Figure 1 and are listed in Supplementary Table S4.
1. Beroukhim, R. et al. The landscape of somatic copy-number alteration across
human cancers. Nature 463, 899–905 (2010).
2. Inaki, K. & Liu, E. T. Structural mutations in cancer: mechanistic and functional
insights. Trends Genet 28, 550–9 (2012).
3. Downing, J. R. et al. The Pediatric Cancer Genome Project. Nat Genet 44, 619–22
(2012).
4. Zhang, J. et al. The genetic basis of early T-cell precursor acute lymphoblastic
leukaemia. Nature 481, 157–63 (2012).
5. Northcott, P. A. et al. Subgroup-specific structural variation across 1,000
medulloblastoma genomes. Nature 488, 49–56 (2012).
6. Robinson, G. et al. Novelmutations target distinct subgroups ofmedulloblastoma.
Nature 488, 43–8 (2012).
7. Medvedev, P., Stanciu, M. & Brudno, M. Computational methods for discovering
structural variation with next-generation sequencing. Nat Methods 6, S13–20
(2009).
8. Wang, J. et al. CREST maps somatic structural variation in cancer genomes with
base-pair resolution. Nat Methods 8, 652–4 (2011).
9. Zhang, J. et al. A novel retinoblastoma therapy from genomic and epigenetic
analyses. Nature 481, 329–34 (2012).
10. Aldridge, B. B., Burke, J. M., Lauffenburger, D. A. & Sorger, P. K. Physicochemical
modelling of cell signalling pathways. Nat Cell Biol 8, 1195–203 (2006).
11. Polakis, P. Wnt signaling in cancer. Cold Spring Harb Perspect Biol 4 (2012).
12. van Amerongen, R. & Nusse, R. Towards an integrated view of Wnt signaling in
development. Development 136, 3205–14 (2009).
13. Cadigan, K.M.Wnt/beta-catenin signaling: turning the switch.Dev Cell 14, 322–3
(2008).
14. Lee, E., Salic, A., Kruger, R., Heinrich, R. &Kirschner, M.W. The roles of APC and
Axin derived from experimental and theoretical analysis of the Wnt pathway.
PLoS Biol 1, E10 (2003).
15. Kim, D., Rath, O., Kolch, W. & Cho, K. H. A hidden oncogenic positive feedback
loop caused by crosstalk between Wnt and ERK pathways. Oncogene 26, 4571–9
(2007).
16. Mirams, G. R., Byrne, H. M. & King, J. R. A multiple timescale analysis of a
mathematical model of the Wnt/beta-catenin signalling pathway. J Math Biol 60,
131–60 (2010).
17. Shin, S. Y. et al. Functional roles of multiple feedback loops in extracellular signal-
regulated kinase and Wnt signaling pathways that regulate epithelial-
mesenchymal transition. Cancer Res 70, 6715–24 (2010).
18. Wawra, C., Kuhl, M. & Kestler, H. A. Extended analyses of the Wnt/beta-catenin
pathway: robustness and oscillatory behaviour. FEBS Lett 581, 4043–8 (2007).
19. Kogan, Y. et al. A new validated mathematical model of the Wnt signalling
pathway predicts effective combinational therapy by sFRP and Dkk. Biochem J
444, 115–25 (2012).
20. Kawano, Y. & Kypta, R. Secreted antagonists of the Wnt signalling pathway.
J Cell Sci 116, 2627–34 (2003).
21. Bao, J., Zheng, J. J. &Wu, D. The Structural Basis of DKK-Mediated Inhibition of
Wnt/LRP Signaling. Sci Signal 5, pe22 (2012).
22. Goentoro, L. & Kirschner, M. W. Evidence that fold-change, and not absolute
level, of beta-catenin dictates Wnt signaling. Mol Cell 36, 872–84 (2009).
23. Weischenfeldt, J., Symmons, O., Spitz, F. & Korbel, J. O. Phenotypic impact of
genomic structural variation: insights from and for human disease.Nat Rev Genet
14, 125–138 (2013).
24.Wharton, K. A., Jr. Runnin’ with theDvl: proteins that associate with Dsh/Dvl and
their significance to Wnt signal transduction. Dev.Biol. 253, 1–17 (2003).
25. Wallingford, J. B. & Habas, R. The developmental biology of Dishevelled: an
enigmatic protein governing cell fate and cell polarity. Development 132,
4421–4436 (2005).
26. Gao, C. & Chen, Y. G. Dishevelled: The hub of Wnt signaling. Cell Signal 22,
717–27 (2009).
27. Lee, H. J. et al. Identification of transmembrane protein 88 (TMEM88) as a
dishevelled-binding protein. J Biol Chem 285, 41549–56 (2010).
28. Cloutier, M. & Wang, E. Dynamic modeling and analysis of cancer cellular
network motifs. Integr Biol (Camb) 3, 724–32 (2011).
29. Jho, E. H. et al.Wnt/beta-catenin/Tcf signaling induces the transcription of Axin2,
a negative regulator of the signaling pathway. Mol Cell Biol 22, 1172–83 (2002).
30. Serinsoz, E. et al. Aberrant expression of beta-catenin discriminates acutemyeloid
leukaemia from acute lymphoblastic leukaemia. Br J Haematol 126, 313–9 (2004).
31. Ellison, D. W. et al. Medulloblastoma: clinicopathological correlates of SHH,
WNT, and non-SHH/WNTmolecular subgroups. Acta Neuropathol 121, 381–96
(2011).
32. Cruciat, C. M. et al. RNA helicase DDX3 is a regulatory subunit of casein kinase 1
in Wnt-beta-catenin signaling. Science 339, 1436–41 (2013).
33. Barker, N. & Clevers, H. Mining the Wnt pathway for cancer therapeutics.
Nat.Rev.Drug Discov. 5, 997–1014 (2006).
34. Polakis, P. Drugging Wnt signalling in cancer. EMBO J 31, 2737–46 (2012).
35. Saez-Rodriguez, J. et al. Discrete logic modelling as a means to link protein
signalling networks with functional analysis of mammalian signal transduction.
Mol Syst Biol 5, 331 (2009).
Acknowledgements
This work was supported by NIH grants CA21765 (Cancer Center Support Grant) and
GM081492 and by the American Lebanese Syrian Associated Charities (ALSAC).We thank
Drs. Tanja Gruber and Amar Gajjar for critical reading of the manuscript and Sharon
Naron for editing the manuscript.
Author contributions
All authors contributed to analysis and interpretation of the data and writing of the
manuscript. J.B. generated the mathematical model. H.-J.L. acquired and summarized the
data. J.J.Z. conceived, designed and supervised the studies.
Additional information
Supplementary information accompanies this paper at http://www.nature.com/
scientificreports
Competing financial interests: The authors declare no competing financial interests.
How to cite this article: Bao, J., Lee, H.-J. & Zheng, J.J. Genome-wide network analysis of
Wnt signaling in three pediatric cancers. Sci. Rep. 3, 2969; DOI:10.1038/srep02969 (2013).
This work is licensed under a Creative Commons Attribution-
NonCommercial-NoDerivs 3.0 Unported license. To view a copy of this license,
visit http://creativecommons.org/licenses/by-nc-nd/3.0
www.nature.com/scientificreports
SCIENTIFIC REPORTS | 3 : 2969 | DOI: 10.1038/srep02969 4
